RxDoctor Payments Data

Vu To, MD

Internal Medicine · Houston, TXNPI 1346622230

Payments from drug & device makers

$14,620in general payments, 2019–2025

Across 889 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • GSK$1K
  • Lilly USA, LLC$956
  • Mannkind Corporation$781
  • plus $8K from 44 others

What the payments were for

  • Food & beverage$14,614100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,620 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$66,122
Medicare patients
142
Services billed
760

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$103,266
FarxigaDapagliflozin Propanediol53$86,510
JardianceEmpagliflozin26$46,647
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$45,918
MounjaroTirzepatide37$43,823
ProliaDenosumab22$38,282
GlyxambiEmpagliflozin/Linagliptin19$30,318
TrulicityDulaglutide11$26,684
EliquisApixaban23$26,358
TrintellixVortioxetine Hydrobromide17$25,405
VascepaIcosapent Ethyl20$20,078
LinzessLinaclotide14$19,952
Repatha SureclickEvolocumab19$17,664
MyrbetriqMirabegron13$16,778
VraylarCariprazine Hcl11$16,150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,318$103,26656 claims
AstraZenecaFarxiga$1,397$86,51053 claims
Boehringer IngelheimJardiance, Glyxambi$608$76,96445 claims
Lilly USA, LLCMounjaro, Trulicity$956$70,50648 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$1,085$53,75564 claims
AmgenProlia$515$38,28222 claims
AbbVieLinzess, Vraylar, Synthroid$1,478$37,33039 claims
PfizerEliquis, Paxlovid$234$27,78741 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$453$25,40517 claims
Astellas Pharma US IncMyrbetriq$282$16,77813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →